Ashis Biswas, Head of Technical Research at CapitalVia Global Research highlights Fundamentals and Technical Analysis on Divi ...

Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q2 2026 earnings on Nov 7, 2025. The consensus estimate for Q2 2026 revenue is $25.86 billion, and the earnings are expected to come in at ...

Divis Laboratories Ltd is quoting at Rs 6722, up 1.07% on the day as on 12:49 IST on the NSE. The stock is up 9.34% in last one year as compared to a 1.62% slide in NIFTY and a 12.19% slide in the ...

Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s ...

HYDERABAD, India--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Divi’s Laboratories (NSE: DIVISLAB), one of the largest active ...

Pharma stocks in India witnessed a sharp rally on Friday, with shares of Cipla, Divi’s Laboratories, Piramal Pharma, and others surging up to 5% amid strong buying momentum. The rally came after ...

India, Jan. 15 -- The shares of this pharma stock, engaged in the manufacturing and exporting of API's and Nutraceutical ingredients, are in focus after leading global brokerage, CITI, has expressed ...

Divi's Laboratories proposes ₹30 per share final dividend for FY25 Stock price reaches record ₹6,764, up 4.37 percent New long-term pharma supply deal triggers ₹650-750 crore investment Shares of ...

Earnings call Divi's Laboratories reported a 17% YoY revenue growth in Q2 FY26, driven by a record 56% contribution from custom synthesis. Margins remained resilient despite ongoing generic pricing ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...